InvestorsHub Logo
Followers 2
Posts 385
Boards Moderated 0
Alias Born 09/20/2017

Re: Spideyboy post# 2554

Friday, 11/09/2018 12:04:24 PM

Friday, November 09, 2018 12:04:24 PM

Post# of 3988
Spideyboy "The 110 Fabry patients includes the earlier studies and the Phase 3".This is the answer from Marcy Nanus to my email.The company has obvious problems with clear presentation of information.It’s pretty obvious that Protalix concentrates all efforts and resources on PRX-102.The company has money for about one year ($42m +$17,5m from Chiesi for development costs next year + some revenue) so it is not critical.What is really critical is the success of PRX-102 and how quickly this success will be achieved.I did't not know Fabrazyme and Galafold do not have a final approval in the US. If PRX-102 gets such approval, will it have any advantage over these two drugs?
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent PLX News